Rocket Pharmaceuticals Narrows Q4 Loss, Holds $188.9M Cash as Kresladi Decision Looms
Rocket Pharmaceuticals posted a Q4 loss of $0.38 per share versus $0.42 expected, while G&A expenses fell 42% to $14.7 million. The company holds $188.9 million in cash, funding operations into Q2 2027, and awaits an FDA decision on its Kresladi BLA by March 28, 2026.
1. Narrowed Q4 Loss and Expense Cuts
Rocket Pharmaceuticals reported a fourth-quarter loss of $0.38 per share versus the $0.42 consensus estimate, reflecting improved cost controls. General and administrative expenses declined 42% year over year to $14.7 million, while research and development spending fell 21.6% to $29.3 million following organizational restructuring.
2. Strong Cash Position and Stock Momentum
As of December 31, 2025, the company held $188.9 million in cash, cash equivalents and investments, sufficient to fund operations and capital requirements into the second quarter of 2027. Shares jumped 6.4% in after-hours trading and have gained 36.7% over the past six months, outpacing the biotech industry’s 22.4% rise.
3. Multiple Pipeline Catalysts Ahead
In October 2025, the FDA accepted the resubmitted BLA for Kresladi, with a decision expected on March 28, 2026, potentially earning a Rare Pediatric Disease Priority Review Voucher. The clinical hold on the pivotal Phase II study of RP-A501 has been lifted, with dosing set to resume in H1 2026, and a Phase I study for RP-A701 is planned by mid-2026.